

Prediction of nanographene binding-scores to trout cellular receptors and cytochromes

Connolly, M., C., Navas, J.M. and Coll, J.*

Department of Environment. Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria, INIA. Madrid, Spain.

short title: nanographenes AHR and CYP bindings

Keywords: nanographene fragment; AHR; CYP; P450; trout; virtual binding; docking; ligands;

Connolly, Mona email: connolly.mona@inia.es orcid: 0000-0003-3574-8564

Navas, Jose Maria email: jmnavas@inia.es orcid: 0000-0002-7644-8499

* Corresponding author Coll, Julio email: juliocollm@gmail.com orcid: 0000-0001-8496-3493

Abstract: To address the increasing concerns surrounding possible impacts of graphene-related materials on the aquatic environment, this study focused on computational predictions of binding between models of graphenes in the nm size range (nanographenes, nGs) and the aryl-hydrocarbon receptor (tAHR) and P450 cytochromes (tCYPs) of rainbow trout (*Oncorhynchus mykiss*). The tAHR plays a key role in the induction of detoxifying and early immune responses and tCYPs are essential for detoxifying planar hydrophobic chemicals such as nGs. After 3D modelling of those trout proteins, docking algorithms predicted the size-dependence profiles of nGs binding-scores to tAHR and tCYPs in the low nM range (high binding-affinities). Virtual oxidations of nGs to nGOs (carboxy-, epoxy- and/or hydroxy-oxidations) further lowered the corresponding binding-scores in level/type-oxidation manners. Among all the tCYPs, the tCYP3AR (the equivalent to human CYP3A4) was identified as a potential key interaction enzyme for nGs because of its lower binding-scores. These results implicate a possible processing pathway to be further probed through *in vitro* and *in vivo* experimentation. Together the information generated can be pivotal for the design of safer graphene-related materials for a variety of applications and help to understand their detoxification in aquatic vertebrates.

Introduction

Graphene-related materials (GRMs) have potential applications in a variety of human activities, from aeronautics to biomedicine, to electronics and in agriculture. This is causing a constant increase in the production of GRMs that will likely lead to releases to the environment during production, use and/or disposal¹. Although the current concentrations and toxicological hazards of GRM in the aquatic media are yet minimal, they are expected to increase with graphene production^{2,4}. Usually, graphene is not used in its pristine form but with a certain degree of oxidations (GOs). GOs have been shown to interact with other environmental pollutants, such as polyaromatic hydrocarbons (PAHs) causing an increase in cytotoxicity as estimated in fish cell lines⁵. Once in the aquatic environment, residues of GOs will likely interact with a variety of biota but there is only a limited knowledge of the bio-reactions they might induce. Among these bio-reactions, perturbations in detoxifying mechanisms⁶ and immune responses⁷⁻⁹ would have important impacts on vertebrates. To better understand the possible initiation of detoxifying bio-reactions induced by or interfering with GOs, we have selected small fragments or nanographenes (nGs) to mimic degradation products of larger sheets. In this study we have focused on the possible effects of pristine nanographenes considering those as a single layer sheet < 100 nm lateral size without (nGs) and with different levels of oxidation (nGOs).

Previous work has shown that nGOs can adhere to the cellular plasma membrane, insert into the lipid bilayers and enter the cytoplasm¹⁰. Once inside the cell, detoxification pathways could be activated that may hypothetically include receptor binding and induction of enzymes that cause a reduction of hydrophobicity by further oxidation (including carboxy- epoxy- and hydroxy-oxidation) to more hydrophilic metabolites which could more easily be excreted via the bile, urine or gills to prevent toxic concentrations and their derived bio-effects^{11,12}. We hypothesize that extracellularly, large graphenes (platelets) may begin their degradation by different mechanisms such as oxidation with reactive oxygen produced by peroxidases^{13,14}, leading to nGO. Alternatively, and although not yet demonstrated, different intramolecular imperfections in the graphene platelets could allow oxidations to occur extracellularly. Once inside cells, nGOs could bind to the aryl-hydrocarbon receptor (AHR) and induce oxidating cytochromes (CYPs), that will feed-back to further accelerate oxidation.

Taking into account the hypothesis mentioned above, we have computationally explored whether nGs/nGOs of ~25-200 rings could bind to intracellular AHR and/or CYPs with enough binding affinity to explain any downstream effects. Given the large differences among nGOs derivatives, it would be most convenient to select only those with the highest likelihood to elicit such bio-reactions that could be then demonstrated through *in vitro* or *in vivo* experimentation. Any reduction in the number of possibilities would make experimentation approaches more targeted and feasible. Therefore, to improve the likelihood of experimental success and to increase our understanding of possible detoxification mechanisms, *in silico* binding predictions between nGs/nGOs and 3D modeled AHR / CYPs has been performed.

For this work, rainbow trout (*Oncorhynchus mykiss*) was selected as a model vertebrate species because of their high sensitivity to environmental pollutants, and widespread use in ecotoxicological studies. Additionally, a number of their detoxifying and immune-related genes and/or functionalities have been studied. Therefore, this work specifically focuses on the trout aryl-hydrocarbon receptor (tAHR) and detoxification cytochrome enzymes such as CYPs (tCYPs).

Single layer graphene is constituted by a series of aromatic rings forming a planar structure. Therefore, Gs/GOs are structurally related to PAHs

which are also constituted by aromatic rings albeit PAHs have a much lower number of rings. Since the AHR is one of the first proteins to recognise the intracellular presence of PAHs, we have hypothesized that the AHR could also bind nGs/nGOs. Once bound to a ligand, the cytoplasmic AHR dissociates from HSP90 and other proteins, binds to the aryl-hydrocarbon receptor nuclear translocator protein (ARNT)¹⁵ and translocates into the cell's nucleus. The co-transcriptional factor AHR/ARNT complex then interacts with xenobiotic genomic DNA response elements (XREs) to induce transcription of *cyps* and many other proteins¹⁶. The recognition of ligands by PAHs has been mapped in mammalian AHRs to their PAS domain (PER, ARNT, SIM) which is common to other proteins of the same family of transcriptional factors. In particular, deletion analysis demonstrated that the binding-domain was localized in the amino-terminal part of AHR at residues 1-403. In contrast, deletion of 398-805 residues had no effect on ligand binding^{17,18}. Mouse AHR mutants at the 375 residue confirmed a reduction of binding of the prototypical ligands¹⁹. Although all the above mentioned properties are most probably similar in trout, confirmatory studies are very scarce and some AHR downstream pathways may differ²⁰.

Detoxification of target aromatic molecules like PAHs, begins with the so called detoxification phase 1 by the addition of -COOH, -O, or -OH, by monooxygenases (predominant), flavoprotein monooxygenases, monamine oxidases, epoxide hydrolases and/or reductases. Among all these possibilities, CYPs were chosen for this study because in vertebrates these oxidative microsomal-membrane heme-containing enzymes are the main participants in phase 1 detoxification²¹. In addition, some of them are induced after ligand binding to AHR and have been studied in rainbow trout²², to such an extent that induction of CYP1 by AHR activation is been used as a biomarker for hydrophobic contaminant exposure^{23,24}. A feed-back loop regulates AHR and CYPs transcription, increasing CYP1 down-regulates *ahr* and inhibition of CYP1 up-regulates *ahr*¹⁶. In human cells, inhibition of CYP1 up-regulates also helper T cells (and other immune cells) while down-regulating *IL7* gene expression²⁵. Furthermore, some of the CYPs effects during infections resemble those of proinflammatory cytokines, further implicating CYPs in inflammation and immunology²⁶.

Putative CYPs predicted in their corresponding genomes (<http://dmnelson.uthsc.edu/cytochromeP450.html>), showed species- and family-specific amino acid sequences²², nevertheless with high tridimensional 3D structural similarities. CYPs are divided into those involved in xenobiotic catabolism (CYP1-4) and those implicated in metabolic biosynthesis (CYP5-51). Some CYPs are constitutively expressed but others are induced by PAHs²⁷. Specifically in fish, many CYP enzymes are known to be implicated in fish metabolic biosynthesis such as that of hydroxycholesterols²⁸, but also several CYP1-4 detoxifying enzyme families have been detected²². Therefore, it is expected that most foreign compounds introduced into the cellular environment of a fish body, including nGs/nGOs, could hypothetically interact with several CYPs as well as with other detoxifying enzymes. Furthermore, structurally distinct nGs/nGOs may have specific binding affinities with different CYPs with either inhibitory or synergistic results.

Therefore, this work focuses on prediction of binding-scores and conformations or binding-poses of pristine nGs and oxidated nGOs with tAHR and tCYPs. To our knowledge, no such computational predictions have been yet reported for any graphene-like or nGs/nGOs to tAHR/tCYPs^{6,29-31}.

Figure 1. Binding-scores of nG-like compounds to hAHR and tAHR.

A) Binding-scores to 83 nG-like compounds compared between hAHR and tAHR.
B) Drawing showing the best pose of 37-ring nG bound to hAHR.
C) Drawing showing the best pose of 37-ring nG bound to tAHR.





Figure 2. Influence of the number of rings of nG in their binding to tAHR and to tCYPs.

nGs of different sizes were designed by the GOPY tool. Black numbers, lateral sizes in nm of the nGs for inputs to the GOPY tool. Black circles, tAHR. Red circles, tCYP1A1. Green circles, tCYP1A3. Blue circles, tCYP3A4.



Modeling of 20x20 nm nGs resulted in nGs of 72 rings down to binding-scores of $>10^{-10}$ nM, compared to those of 25 nG or 37 circumcircumcoronene rings which bound to the hAHR / tAHR with binding-scores in the $\sim 10^{-3}$ nM range (Figure 1A). To further investigate the influence of nG size in the binding to tAHR and tCYPs, different sizes were designed and computationally tested by blind docking (PAS tAHR domain) or binding-pocket docking (tCYPs).

The results predicted that the lower binding-scores to tAHR corresponded to nGs > 100 -rings. Larger nGs maintained these binding-scores. Binding to tCYPs showed a similar size-profiles as to tAHR, but in the 10^{-5} - 10^{-9} binding-score ranges (Figure 2, blue, green and red lines). Most tAHR binding to nGs mapped to its PAS ligand binding site. In contrast, most nGs binding to CYPs were localized on their surfaces away from their heme sites, suggesting some unspecific bindings (Figure S2). Only 4-9-ring nGs were mapped nearby to their heme site, most probably because only such small compounds could penetrate through the CYP tunnels to such internal location to be specifically oxidized (Figure S2).

Models of 9 (7x7 nm, 32 Carbons) and 25 (13x13 nm, 77 Carbons)-ring nGs were selected for further studies, because significant binding-scores could be obtained in minimal computational times.

Computational binding of nGOs to tAHR

Carboxy (-COOH), epoxy (-O-) and hydroxy (-OH) oxidations were mimicked by adding them to the 9 and 25-ring nGs to randomly generate their corresponding nGOs using 1.6 Carbon/Oxygen C/O ratios ¹⁰ (see some of their structures in Figure S3).

In this test, docking conditions were adjusted to yield binding-scores of $\sim 10^{-3}$ nM and $\sim 10^{-1}$ nM for 25- and 9-rings nGs, respectively. Results with nGOs predicted 10^{-1} - 10^{-7} nM binding-scores for 25-rings (Figure 3,) and 10^0 nM for most 9-rings (Figure 3, red- and grey-edged circles, respectively). In particular, epoxidation (-O-) alone or in combination with carboxylation (-COOH), was the most efficient process to reduce the binding-scores of 25-ring nGOs. In contrast, hydroxylation (-OH), and its combinations increased their binding-scores.

Mapping of the corresponding 3D binding-poses predicted that the amino terminal end of the PAS domain of tAHR was targeted by most 25- and 9-rings nGOs (Figure 3C and B, respectively).




Figure 3. Influence of nG oxidation (nGO) in the binding-scores to tAHR. Oxidations with -COOH, -O-, -OH and combinations of them were randomly added at maximal C/O ~ 1.6 ratios to 9 or 25-ring nG using the GOPY tool.

A) Grey-edged circles, 9-ring nGO.
Red-edged circles, 25-ring nGO.
Grey-edge, red filled circle, 9-ring nG.
Red-edge red filled circle, 25-ring nG.
Black vertical lines, separation between different types of oxidations.
Dashed horizontal blue lines, nGs binding-scores to tAHR.
B) Mapping of 9-ring nGOs bindings to tAHR.
C) Mapping of 25-ring nGOs bindings to tAHR.




Figure 4. Influence of the level of oxidation in the binding of nGs to tAHR. Individual -COOH, -O-, -OH oxidant molecules were randomly added into 25 rings (77 Carbons) nGs by the GOPY tool. From 5-10 nG molecules were randomly oxidized per each level of oxidation. Due to steric problems when > 20 -30 atoms were added, some of the resulting nGO structures when examined in PyMOL, only approximately confirmed the initial numbers supplied to the tool. Theoretical oxidations per nG molecule were expressed in % as calculated by the formula, $100 \times \text{number of output oxidative molecules per 77 Carbons}$. Black big square and blue-dashed horizontal line, binding-scores of 5x5 nm nGs (mean of $n=5$). Red circles, nG-COOH. Green circles, nG-O. Blue circles, nG-OH.

Computational binding of nGOs with different oxidation levels

To study the influence of the levels of nGO oxidation on the binding to tAHR, different numbers of oxygen-containing molecules were added to 25-ring nGs. Results showed that increasing the level of peroxidation (-O-) to 70 % caused a continuous reduction to 10^{-4} nM binding-scores (Figure 4, green circles). Increasing the level of carboxylation (-COOH) or hydroxylation (-OH) to < 25 % reduced their binding-scores to $\sim 10^{-5}$ - 10^{-6} nM, but increased them at higher oxidation levels (Figure 4, red and blue circles). Both nG and most nGO binding-scores to tAHR remained $< 10^1$ nM, which may be significant compared to the 10^3 nM binding-score of the AHR prototypical agonist TCDD under the same docking conditions.

Because of the nGs tendency to bind non-specifically to tCYPs (Figure S2), the size of the nGs were reduced to 5x5 nm (4 rings) and grids of 25 x 30 x25 Å surrounding the tCYPs heme were used for docking.

Under the above mentioned conditions, the nG binding-scores varied for each tCYPs molecular species from 10^2 to 10^4 nM (Figure 5, black-dashed horizontal lines). By increasing the level of nGOs oxidation to ~ 25 % most binding-scores decreased to different minimal levels for different tCYPs. However, increasing the level of most oxidations > 25 %, resulted in increased binding-scores for most tCYPs, except tCYP3AR. Thus, with >25 % oxidations, tCYP3AR binding-scores were further reduced to 10^{-2} by carboxylation (Figure 5, 3AR, red circles), and to a lower extent by peroxidation and hydroxylation.

Discussion

Lateral sizes of commercial powered graphene are of ~10 nm while the so called nanoplatelets range between 20-100 nm for oxidized graphene (GO) and between 100-1000 nm for carboxylated graphene ¹⁰. Our initial working hypothesis was that larger graphene fragments (e.g., platelets) are broken down and taken up by trout cells transformed into smaller graphene pieces of ~10-100 rings (graphenes in the nm size range, here called nGs). We hypothesized that once internalized by cells, nGs/nGOs may interact with microsomal tAHR activating phase I detoxification mechanisms, such as those implicating peroxidase-dependent reactive oxygen ^{13, 14} and/or tCYPs enzymatic activities/*tcyp* gene transcription, to induce other bioeffects. All these possibilities remain largely unexplored.

To test such hypothesis by *in vitro* and *in vivo* experimentation, given the large numbers of different nGs/nGO derivatives, their numbers need to be reduced and possible candidates identified for further experimental studies. To do that, we proposed an *in silico* screening to select for those nGs with the highest binding affinities (lower binding-scores) to tAHR and tCYPs. We discovered that the maximal number of nG rings that tAHRs/tCYPs could bind is up to 25-rings with apparent binding-scores between 10^3 - 10^{11} nM and mapping to the PAS tAHR specific binding site defined by its prototypical TCDD ligand.

Increasing hydrophilicity that facilitates detoxification of graphenes, is mostly caused by carboxylation, peroxidation and/or hydroxylation, but ring-opening and reduction may also be implicated ⁴³. Oxidation of nGs to nGOs by virtually adding -COOH, -O- and -OH such as those expected to be found in most graphenes used for biomedical applications, computationally predicted between 10-100-fold reduction in their nG binding-scores to tAHR depending on the numbers of oxidized carbons per molecule and the type of oxidation. Additionally, any possible implication of tCYPs in nG binding and subsequent oxidation may be sterically possible only with the smallest nGs according to the computational data. Predicted conformation or pose analysis showed that although nGs could bind tCYPs, most of those bindings seem to be unspecific or not specifically oxidative because of their excessive separation from the inner tCYP heme where oxidation is expected to be most active. Pose bindings nearby the tCYP heme could not be visualized for nGs > 4 rings. Only the minimal nGs of 4 rings were small enough to penetrate the inner heme located within the predicted binding pockets.

With such size restrictions, among all the CYPs, the tCYP3AR was predicted to bind stronger than other tCYPs to nGOs, specifically to those which were carboxylated at their edges. Perhaps the higher implication of tCYP3AR in additional oxidations compared to other tCYPs may be due to its participation in the metabolism of endogenous substrates, such as steroids ⁴³. According to the UNIPROT data base, tCYP3AR is coded by the trout gene *cyp3a27*, however 3D modeling choose the human hCRP3A4 as the closest isomer, suggesting that despite nucleotide sequence differences, tCYP3AR is equivalent to hCYP3A4. Although our knowledge of any tCYPs is still scarce, immunologically relatedness of fish CYP3A to hCYT3A4 and rat CYP3A has been demonstrated ⁴⁴. However, since there is evidence that tCYP3A4 shows no significant bio-effects to seven known substrates of the corresponding hCYP3A4 ⁴⁵, the impact of substrate oxidation may differ among species. The hCYP3A subfamily is the most important of drug-metabolizing enzymes since it accounts for ~30 % of the total CYPs in the liver and metabolizes ~50 % of marketed drugs ⁴³. In humans it is being expressed mainly in the liver where it accounts for 13 % of the total CYP content and has been implicated in the metabolism of ~4% of marketed drugs ⁴³. In contrast, few data are available for tCYP3AR.

The computational predictions identified the nGs molecular characteristics required to be suitable ligands for tAHR and therefore those with the higher potential to generate bio-effects. It may be hypothesized that subsequent translocation into the nucleus to induce the numerous tAHR-dependent genes would sustain the bases for a link between the environment and toxicological and immune responses at the cellular level. Although there are still no experimental evidences for that possibility, the present results indicate this may deserve further explorations.

On the other hand, since vertebrate AHRs are expressed in many cells of both innate and adaptive immunity, the AHR may be one of the translators of environmental hydrophobic contamination into immunological responses. Experimental validation of such hypothesis, could be performed by *in vitro* and/or




Figure 5. Influence of the level of oxidation in the binding of nGOs to tCYPs. Individual -COOH, -O-, -OH oxidant molecules were virtually and randomly added into 4 rings, 18 Cs nGs by the GOPY tool. From 5-10 nG molecules were virtually oxidated per each level of oxidation. Due to steric problems when > 20-30 atoms were added, some of the resulting structures examined in PyMOL only approximately confirmed the initial numbers supplied to the tool. Theoretical oxidations per nG molecule were expressed in % as calculated by the formula, $100 \times \text{number of oxidation molecules provided to the GOPY tool} / 18$ (n=5). The CYP family is in black bold lettering placed at around the 10^2 nM label for easy reference. Only those nGs showing binding affinities < 10^5 nM were shown. All the scales were equal except the wider lower scale down to 10^{-2} for tCYP3AR. Black big square and dashed horizontal line, binding-scores of 5x5 nm nGs (mean of n=5). Red circles, nGO-COOH. Green circles, nGO-O-. Blue circles, nGO-OH.

in vivo assays by measuring the effect of synthetic nGs and their nGOs oxidated derivatives with different levels of oxidation, similar to those which have been investigated here using *in silico* screening.

Among the main difficulties to experimentally validate any hypothesis related to nG/nGO is the lack of such molecularly defined graphenes. An alternative to obtain the corresponding nGs/nGOs for experimental purposes could include not only chemical synthesis (if chemical synthesis could make it possible) but also strong sonication techniques or long peroxidation of graphene platelets. Techniques for removal of the largest fragments by ultracentrifugation and/or gel filtration chromatography are available. However, more detailed molecular characterization of such preparations than those routinely employed may also be required.

For further downstream experimentation, several *in vitro* assays such as those using subcellular fractions, fish cell lines, hepatocytes and/or tissues ²⁴, could be used. Specifically to detect a variety of tAHR induced genes, for instance, RTqPCR could be used to detect up-/down-regulation of selected *tcyps*. Any induced tCYP1A and/or tCYP3A enzyme activities can also be monitored using ethoxyresorufin-O-deethylase (EROD) or benzyloxy-4-trifluoromethylcoumarin-O-debenzyloxyase (BFCOD) activity assays, respectively. To estimate possible induced immunological responses and/or to explain differences among AHR modulations observed across species⁴⁶, concentration-dependent effects on trout immunosuppression ²⁵, inflammation (downregulation of *il6*, *crp*, or upregulation of *tgfb*) and/or T cell and macrophage activation ⁴⁷, may also be performed. Combining the information generated by *in silico* screening with future *in vitro* and *in vivo* experimentation, forms an integrative approach for unveiling the bio-interactions and effects induced by nGs/nGOs and expanding our knowledge of these highly bio-interactive planar hydrophobic substances.

SUPPORTING INFORMATION

Table S1. Trout CYPs CLUSTAL O(1.2.4) sequence alignment

093299	CP2K3_ONCMY	-----MSLIEGLQTSSTVTL-----LGTVLFLVLV-----LRSSGSSSEQ	38
092110	CP1A1_ONCMY	MVLMILPIIGSVSVSEGLVAIVTLGLVYM-----LMKY-----KHTEIPEGLKK	44
092109	CP1A3_ONCMY	-----MMVSVSVCRSSSLALPACGLPSARHNSMPVVRQALSPDNSTVQN	45
092090	CP2K1_ONCMY	-----MSLIEGLQTSSTVTL-----LGTVLFLVLV-----LRSSGSSSEQ	38
092088	CP2M1_ONCMY	-----MDVL-HILQTNFVSI-----IGFVVIILL-W-----MNRGQSN	33
093297	CP2K4_ONCMY	-----MSLIEGLQTSSTVTL-----LGTVLFLVLV-----LRSSGSSSEQ	38
042563	CP3AR_ONCMY	-----MMSFLPYFS-----AETWTLLALLITL-----I-V-----VGYWVPYGVFT	35
093299	CP2K3_ONCMY	GKEPPGPR---PLDLLGNMLQLD-LKKPYT TLGLSLK YGSIFTFHGP PKKVVV LAGEYKT	95
092110	CP1A1_ONCMY	LPGPK-----PLPIIGNLVLE---YNNPHLSLTAMSER YGS VFQIQ IMR PVVVLSGNETV	97
092109	CP1A3_ONCMY	FSEIPGLWRNGLANLYSFWKLDGFRNIRHVMHNFNT GP IYREK IGYDS VNI IK PEMP	105
092090	CP2K1_ONCMY	GKEPPGPR---PLDLLGNMLQLD-LKKPYT TLGLSLK YGSIFTFHGP PKKVVV LAGEYKT	95
092088	CP2M1_ONCMY	SRLPGGPA---DIPDLLGNLMD-LKKPYT TLGLSLK YGSIFTFHGP PKKVVV LAGEYKT	95
093297	CP2K4_ONCMY	GKEPPGPR---PLDLLGNMLQLD-LKKPYT TLGLSLK YGSIFTFHGP PKKVVV LAGEYKT	95
042563	CP3AR_ONCMY	KMGIPGPK---PLPYFTGLMEYK---KGFNTFT ECQK YGR IGW IGY GR Q PVL CI MD KSMI	91
093299	CP2K3_ONCMY	KQALVNOAED-RRDDI-----TPVFYDF-NQGHGILFA---NGDSW KEMR FALTNL	143
092110	CP1A1_ONCMY	RQALIKQGED-FAGRPD-----LYSPFKI-NDGSLAFSTDKAGVNR AK KLAMSA	147
092109	CP1A3_ONCMY	AILFKA---EGHYDKLTVEAMTSYRDYRNRKYGVLLK---NGEDWR SNR VILNR EV SPK	161
092090	CP2K1_ONCMY	KQALVNOAED-FGDRDI-----TPVFYDF-NQGHGILFA---NGDSW KEMR FALTNL	143
092088	CP2M1_ONCMY	KQALIKQGED-FAGRPD-----LYSPFKI-NDGSLAFSTDKAGVNR AK KLAMSA	147
093297	CP2K4_ONCMY	KQALVNOAED-FGDRDI-----TPVFYDF-NQGHGILFT---NGDSW KEMR FALTNL	143
042563	CP3AR_ONCMY	KTVLKECYNIFTNRRN---FHLNGL-----FDALSVAEEDTWRR RS VLSP SPT SGRL	143
093299	CP2K3_ONCMY	-RDFG MG -KK-----GSEKILEEIPYLIEVEFKH---EGKAFDTTQSVLYAVSNIISA	192
092110	CP1A1_ONCMY	-RSPATL-EGTTP YS GALEEHV KE GEVYL Q TSVMDVSGSPDPFHRIIVSVAMV IG	205
092109	CP1A3_ONCMY	-RSPATL-EGTTP YS GALEEHV KE GEVYL Q TSVMDVSGSPDPFHRIIVSVAMV IG	205
092090	CP2K1_ONCMY	-RDFG MG -KK-----GSEKILEEIPYLIEVEFKH---EGKAFDTTQSVLYAVSNIISA	192
092088	CP2M1_ONCMY	-RDFG MG -KK-----GSEKILEEIPYLIEVEFKH---EGKAFDTTQSVLYAVSNIISA	192
093297	CP2K4_ONCMY	-RDFG MG -KK-----GSEKILEEIPYLIEVEFKH---EGKAFDTTQSVLYAVSNIISA	192
042563	CP3AR_ONCMY	KEM IG -IM-KQHSSTLLSGMQDQDKD-----QTI VE KEFFG YS SMV VT S	187
093299	CP2K3_ONCMY	IVYGSRF---EYTDPLFTGMADRAKESHLTGASIQMNMFWLGPWINN-LTRLK	246
092110	CP1A1_ONCMY	MCFGRRY---SHDDQELLGLVMSDEFQGVGSG--NPADFIPILRLPNTRMKR MD	258
092109	CP1A3_ONCMY	VLYGERGLMDLYINPEAQHFIDCISIMFKTTS PM LYIP PA MLRVRGAKIWRD VE AWD	270
092090	CP2K1_ONCMY	MCFGRRY---SHDDQELLGLVMSDEFQGVGSG--NPADFIPILRLPNTRMKR MD	258
092088	CP2M1_ONCMY	IVYGSRF---EYTDPLFTGMADRAKESHLTGASIQMNMFWLGPWINN-LTRLK	246
093297	CP2K4_ONCMY	IVYGSRF---EYTDPLFTGMADRAKESHLTGASIQMNMFWLGPWINN-LTRLK	246
042563	CP3AR_ONCMY	TAFSDVDSLNNSDPFSVSNV KML K---FDLPNPLFLVALLFFPTG IL ER KMK FSF PT	244
093299	CP2K3_ONCMY	NIADMKMEVTLVRGLKETLNP HC R-GPVDVSLVRKQTL ES SGH-----DSFYHDDNL	300
092110	CP1A1_ONCMY	INDRFNNFQKIVSHYSEYDKN IR -DITDSLIDHCE DR KL DEN A-----NIQVSD EKI	312
092109	CP1A3_ONCMY	IFNQADRCIQNIYTRMRQDNTN HK YPGVLS LL M-----LDKLS IED I	314
092090	CP2K1_ONCMY	NIADMKMEVTLVRGLKETLNP HC R-GPVDVSLVRKQTL ES SGH-----DSFYHDDNL	300
092088	CP2M1_ONCMY	NIADMKMEVTLVRGLKETLNP HC R-GPVDVSLVRKQTL ES SGH-----DSFYHDDNL	300
093297	CP2K4_ONCMY	NIADMKMEVTLVRGLKETLNP HC R-GPVDVSLVRKQTL ES SGH-----DSFYHDDNL	300
042563	CP3AR_ONCMY	AVTDFYASLAKISGRD TG NS TR V-DPLFNPFLVALLFFPTG IL ER KMK FSF PT	244
093299	CP2K3_ONCMY	VFSVGNLF SAG TDTTGTTLRWGLLLMTKYPHIQDQ Q VE IS SRVIG-SRQTLVEDRKNLP	359
092110	CP1A1_ONCMY	VGIVNDL FAG FDTTISTALSAAVVLVAVP Q ERL HO LE KE KVGMIRTPRL SD KNL PL	372
092109	CP1A3_ONCMY	VGIVNDL FAG FDTTISTALSAAVVLVAVP Q ERL HO LE KE KVGMIRTPRL SD KNL PL	372
092090	CP2K1_ONCMY	VFSVGNLF SAG TDTTGTTLRWGLLLMTKYPHIQDQ Q VE IS SRVIG-SRQTLVEDRKNLP	359
092088	CP2M1_ONCMY	VFSVGNLF SAG TDTTGTTLRWGLLLMTKYPHIQDQ Q VE IS SRVIG-SRQTLVEDRKNLP	359
093297	CP2K4_ONCMY	VFSVGNLF SAG TDTTGTTLRWGLLLMTKYPHIQDQ Q VE IS SRVIG-SRQTLVEDRKNLP	359
042563	CP3AR_ONCMY	LSQAMIF FAG TDTSSTMSFLAYNLATYHVM TK Q Q VE IS SRVIG-SRQTLVEDRKNLP	359
093299	CP2K3_ONCMY	TDV IH ET Q RLAN IA MP SI PH TS SRD VT Q Q Y PI K-----DSEW ES PH TL	406
092110	CP1A1_ONCMY	LEAFIL EL FRHSS FL PT PH CTIKD TS LNGY PI KD TC VP IN Q W NR DP PE KE SS F	432
092109	CP1A3_ONCMY	LEAFIL EL FRHSS FL PT PH CTIKD TS LNGY PI KD TC VP IN Q W NR DP PE KE SS F	432
092090	CP2K1_ONCMY	TDV IH ET Q RLAN IA MP SI PH TS SRD VT Q Q Y PI K-----DSEW ES PH TL	406
092088	CP2M1_ONCMY	TDV IH ET Q RLAN IA MP SI PH TS SRD VT Q Q Y PI K-----DSEW ES PH TL	406
093297	CP2K4_ONCMY	TDV IH ET Q RLAN IA MP SI PH TS SRD VT Q Q Y PI K-----DSEW ES PH TL	406
042563	CP3AR_ONCMY	LD CV LN ES RL Y IA PL R ER VA KT VEIN GI VP KD CI VL VP TW TL HR DE IS DP EE F	419
093299	CP2K3_ONCMY	TPSHFLDERGGFV---KRD AF MA S AG RR V CL GE L AR ME L FL FT SL L Q RF RP SP PG V	463
092110	CP1A1_ONCMY	NPDRFLSADGT EL N KE GV LV FG MD K RR IG RA IG R NE V VL LA IL LL Q RL RF Q EP K GH	492
092109	CP1A3_ONCMY	NPDRFLSADGT EL N KE GV LV FG MD K RR IG RA IG R NE V VL LA IL LL Q RL RF Q EP K GH	492
092090	CP2K1_ONCMY	TPSHFLDERGGFV---KRD AF MA S AG RR V CL GE L AR ME L FL FT SL L Q RF RP SP PG V	463
092088	CP2M1_ONCMY	DPGRFLNEEGTGLCI-PPSP SY L P AG GR V CL GE L AR ME L FL FT SL L Q RF RP SP PG V	478
093297	CP2K4_ONCMY	NPDRFLSADGT EL N KE GV LV FG MD K RR IG RA IG R NE V VL LA IL LL Q RL RF Q EP K GH	492
042563	CP3AR_ONCMY	K PE RS KE NS ES ---D PT Y TP MP AG GR NG IG MR FAL IM IK L AM VS IL Q ST FS VC DET	476
093299	CP2K3_ONCMY	TEDDLDLTP S VE-FT HN SP S ---H Q L CA VS R -----491	
092110	CP1A1_ONCMY	PLDMT-----PEYGL TM KH---K R Q L K AS M-RPW Q EE-----522	
092109	CP1A3_ONCMY	EVHST-----FELL L PE K PI LL TL K PL S -----G Q -----514	
092090	CP2K1_ONCMY	PLDMT-----PEYGL TM KH---K R Q L K AS M-RPW Q EE-----522	
092088	CP2M1_ONCMY	PLPSL---E---G K FG VL Q P ---V K Y KN AT PR AG WE K SH ---L Q TS---514	
093297	CP2K4_ONCMY	TEDDLDLTP L L G -FT L HP S P S ---H Q L CA VS R -----504	
042563	CP3AR_ONCMY	EIP LE -----MD N Q L L MP K-R PI K L R L EA RR NT PS NT AT L K SP TT 518	

Conserved Cysteines are in bold and green backgrounds while other conserved amino acids in all trout CYPs and/or their similar surrounding amino acids to such positions are in bold red lettering. Similar conserved amino acids (-).

Figure S1. 2D scheme of trout modelled CYP molecule and its predicted binding pockets. The figure shows the amino acid sequence in grey and the heme in green (up in lines and down in spheres) occupying an internal part of CYPs. A tunnel-like with an opening to the left in the drawing (Grey arrow) may support a possible way through which substrates and/or inhibitors may get close to the heme for optimal oxidation (ligand binding pocket). Most of the crystalized ligands map to that heme binding-pocket (yellow background). Between 6-15 other binding pockets were predicted by seeSAR depending on the CYPs (different color backgrounds in the down figure)




Figure S2. Drawings of nGs of different sizes bound to tAHR (up) and tCYPs (down). AutoDock Vina used a whole molecule grid (blind-docking). The nGs of 4 (5x5 nm), 9 (7x7 nm), 12 (10x10 nm), 20 (12x12 nm), 25 (13x13 nm), 36 (15x15 nm), 72 (20x20 nm), 100 (25x25 nm), and 156 (30x30 nm) rings were designed using the GOPY tool. Representative cartoons were made by combining one molecule of protein with several sizes of nG molecules and drawn in PyRx. The heme at the inner part of the CYP molecules have been removed for clarity.




Figure S3. Cartoons of the nGOs of 25 rings (13x13 nm) designed by the GOPY tool. All the drawings were made in PyMOL.

Funding

This research was funded in part by the European Union's Horizon 2020 research and innovation programme (NanoReg2, Grant Agreement n° 646221).

Competing interests

The authors declare that they have no competing interests

Authors' contributions

MC and JN, collaborated by critically discussing strategies and writing and correcting the manuscript. JC performed and analyzed the computational work and drafted the manuscript. Authors read and approved the manuscript.

Acknowledgements

Thanks are due to Dra Ana Valdehita for her help to obtain additional seeSAR licenses. Mona Connolly received financing granted by the Community of Madrid (2018-T2/AMB-11392, Mode 2, Young Doctor Recruitment).

References

- Dasari Shareena, T.P., D. McShan, A.K. Dasmahapatra and P.B. Tchounwou. A Review on Graphene-Based Nanomaterials in Biomedical Applications and Risks in Environment and Health *Nanomicro Lett.* 2018, 10. <https://dx.doi.org/10.1007/s40820-018-0206-4>
- Enma, M., M. Gamo and K. Honda. A review of toxicity studies on graphene-based nanomaterials in laboratory animals *Regul Toxicol Pharmacol.* 2017, 85: 7-24. <https://dx.doi.org/10.1016/j.yrtph.2017.01.011>
- Xiong, G., Y. Deng, X. Liao, J. Zhang, B. Cheng, Z. Cao and H. Lu. Graphene oxide nanoparticles induce hepatic dysfunction through the regulation of innate immune signaling in zebrafish (Danio rerio) *Nanotoxicology.* 2020: 1-16. <https://dx.doi.org/10.1080/17435390.2020.1735552>
- Ou, L., B. Song, H. Liang, J. Liu, X. Feng, B. Deng, . . . L. Shao. Toxicity of graphene-family nanoparticles: a general review of the origins and mechanisms *Part Fibre Toxicol.* 2016, 13: 57. <https://dx.doi.org/10.1186/s12989-016-0168-y>
- Lammel, T., P. Boisseaux and J.M. Navas. Potentiating effect of graphene nanomaterials on aromatic environmental pollutant-induced cytochrome P450 1A expression in the topminnow fish hepatoma cell line PLHC-1 *Environ Toxicol.* 2015, 30: 1192-204. <https://dx.doi.org/10.1002/tox.21991>
- Pan, Y., C.E. Ong, Y.F. Pung and J.Y. Chiang. The current understanding of the interactions between nanoparticles and cytochrome P450 enzymes - a literature-based review *Xenobiotica.* 2019, 49: 863-876. <https://dx.doi.org/10.1080/00498254.2018.1503360>
- Orecchioni, M., D. Bedognetti, F. Sgarrella, F.M. Marincola, A. Bianco and L.G. Delogu. Impact of carbon nanotubes and graphene on immune cells *J Transl Med.* 2014, 12: 138. <https://dx.doi.org/10.1186/1479-5876-12-138>
- Orecchioni, M., D.A. Jasim, M. Pescatori, R. Manetti, C. Fozza, F. Sgarrella, . . . L.G. Delogu. Molecular and Genomic Impact of Large and Small Lateral Dimension Graphene Oxide Sheets on Human Immune Cells from Healthy Donors *Adv Healthc Mater.* 2016, 5: 276-87. <https://dx.doi.org/10.1002/adhm.201500606>
- Orecchioni, M., C. Menard-Moyon, L.G. Delogu and A. Bianco. Graphene and the immune system: Challenges and potentiality *Adv Drug Deliv Rev.* 2016, 105: 163-175. <https://doi.org/10.1016/j.addr.2016.05.014>
- Lammel, T., P. Boisseaux, M.L. Fernandez-Cruz and J.M. Navas. Internalization and cytotoxicity of graphene oxide and carboxyl graphene nanoplatelets in the human hepatocellular carcinoma cell line Hep G2 *Part Fibre Toxicol.* 2013, 10: 27. <https://dx.doi.org/10.1186/1743-8977-10-27>
- Markovic, M., A. Kumar, I. Andjelkovic, S. Lath, J.K. Kirby, D. Losic, . . . M.J. McLaughlin. Ecotoxicology of manufactured graphene oxide nanomaterials and derivation of preliminary guideline values for freshwater environments *Environ Toxicol Chem.* 2018, 37: 1340-1348. <https://dx.doi.org/10.1002/etc.4074>
- Markovic, M., I. Andjelkovic, J. Shuster, L. Janik, A. Kumar, D. Losic and M.J. McLaughlin. Addressing challenges in providing a reliable ecotoxicology data for graphene-oxide (GO) using an algae (Raphidocelis subcapitata), and the trophic transfer consequence of GO-algae aggregates *Chemosphere.* 2020, 245: 125640. <https://doi.org/10.1016/j.chemosphere.2019.125640>
- Kurapati, R., C. Backes, C. Menard-Moyon, J.N. Coleman and A. Bianco. White Graphene undergoes Peroxidase Degradation *Angew Chem Int Ed Engl.* 2016, 55: 5506-11. <https://dx.doi.org/10.1002/anie.201601238>
- Kurapati, R. and A. Bianco. Peroxidase mimicking DNAszymes degrade graphene oxide *Nanoscale.* 2018, 10: 19316-19321. <https://dx.doi.org/10.1039/c8nr06535g>
- Grans, J., B. Wassmur and M.C. Celander. One-way inhibiting cross-talk between arylhydrocarbon receptor (AhR) and estrogen receptor (ER) signaling in primary cultures of rainbow trout hepatocytes *Aquat Toxicol.* 2010, 100: 263-70. <https://doi.org/10.1016/j.aquatox.2010.07.024>
- Grans, J., B. Wassmur, M. Fernandez-Santosoy, J. Zanette, B.R. Woodin, S.I. Karchner, . . . M.C. Celander. Regulation of pregnane-X-receptor, CYP3A and P-glycoprotein genes in the PCB-resistant killifish (Fundulus heteroclitus) population from New Bedford Harbor *Aquat Toxicol.* 2015, 159: 198-207. <https://doi.org/10.1016/j.aquatox.2010.07.013>
- Fukunaga, B.N., M.R. Probst, S. Reisz-Porszasz and O. Hankinson. Identification of functional domains of the aryl hydrocarbon receptor *J Biol Chem.* 1995, 270: 29270-8. <https://dx.doi.org/10.1074/jbc.270.49.29270>
- Whitlock, J.P., Jr. Induction of cytochrome P4501A1 *Annu Rev Pharmacol Toxicol.* 1999, 39: 103-25. <https://dx.doi.org/10.1146/annurev.pharmtox.39.1.103>
- Poland, A., D. Palen and E. Glover. Analysis of the four alleles of the murine aryl hydrocarbon receptor *Mol Pharmacol.* 1994, 46: 915-21. <https://doi.org/10.1093/toxsci/kfr240>
- Wassmur, B., J. Grans, P. Kling and M.C. Celander. Interactions of pharmaceuticals and other xenobiotics on hepatic pregnane X receptor and cytochrome P450 3A signaling pathway in rainbow trout (Oncorhynchus mykiss) *Aquat Toxicol.* 2010, 100: 91-100. <https://doi.org/10.1016/j.aquatox.2010.07.013>
- Renaud, H.J., J.Y. Cui, M. Khan and C.D. Klaassen. Tissue distribution and gender-divergent expression of 78 cytochrome P450 mRNAs in mice *Toxicol Sci.* 2011, 124: 261-77. <https://doi.org/10.1093/toxsci/kfr240>
- Uno, T., M. Ishizuka and T. Itakura. Cytochrome P450 (CYP) in fish *Environ Toxicol Pharmacol.* 2012, 34: 1-13. <https://doi.org/10.1016/j.etap.2012.02.004>
- Jonsson, M.E., K. Gao, J.A. Olsson, J.V. Goldstone and I. Brandt. Induction patterns of new CYP1 genes in environmentally exposed rainbow trout *Aquat Toxicol.* 2010, 98: 311-21. <https://doi.org/10.1016/j.aquatox.2010.03.003>
- Katagi, T. In vitro metabolism of pesticides and industrial chemicals in fish *J Pestic Sci.* 2020, 45: 1-15. <https://doi.org/10.1584/jpestics.D19-074>
- Effner, R., J. Hiller, S. Eyerich, C. Traidl-Hoffmann, K. Brockow, M. Triggiani, . . . J.T. Buters. Cytochrome P450s in human immune cells regulate IL-22 and c-Kit via an AHR feedback loop *Sci Rep.* 2017, 7: 44005. <https://doi.org/10.1038/srep44005>
- Stavropoulou, E., G.G. Pircalabioru and E. Beztzoglou. The Role of Cytochromes P450 in Infection *Front Immunol.* 2018, 9: 89. <https://doi.org/10.3389/fimmu.2018.00089>
- Muntane-Relat, J., J.C. Ourlin, J. Domergue and P. Maurel. Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture *Hepatology.* 1995, 22: 1143-53. <https://doi.org/10.1002/hep.1091003569>
- Bello-Perez, M., A. Falco, B. Novoa, L. Perez and J. Coll. Hydroxycholesterol binds and enhances the anti-viral activities of zebrafish monomeric c-reactive protein isoforms *PLoS One.* 2019, 14: e0201509. <https://doi.org/10.1371/journal.pone.0201509>
- Tian, S., Y. Djoumbou-Feunang, R. Greiner and D.S. Wishart. CypReact: A Software Tool for in Silico Reactant Prediction for Human Cytochrome P450 Enzymes *J Chem Inf Model.* 2018, 58: 1282-1291. <https://doi.org/10.1021/acs.jcim.8b00035>
- Tan, B.H., Y. Pan, A.N. Dong and C.E. Ong. In vitro and in silico Approaches to Study Cytochrome P450-Mediated Interactions *J Pharm Pharm Sci.* 2017, 20: 319-328. <https://doi.org/10.18433/j3434R>
- Zhang, T., Q. Chen, L. Li, L.A. Liu and D.Q. Wei. In silico prediction of cytochrome P450-mediated drug metabolism *Comb Chem High Throughput Screen.* 2011, 14: 388-95. <https://doi.org/10.1002/psm.201202508>
- Lammel, T. and J.M. Navas. Graphene nanoplatelets spontaneously translocate into the cytosol and physically interact with cellular organelles in the fish cell line PLHC-1 *Aquat Toxicol.* 2014, 150: 55-65. <https://doi.org/10.1016/j.aquatox.2014.02.016>
- Muraru, S., J.S. Burns and M. Ionita. GOPY: a tool for building 2D graphene-based computational models *SoftwareX.* 2020, 12: 100586. <https://doi.org/10.1016/j.softx.2020.100586>
- Andon, F.T., A.A. Kapralov, N. Yanamala, W. Feng, A. Baygan, B.J. Chambers, . . . V.E. Kagan. Biodegradation of single-walled carbon nanotubes by eosinophil peroxidase *Small.* 2013, 9: 2721-9. <https://doi.org/10.1002/smll.201202508>
- Trott, O. and A.J. Olson. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading *J Comput Chem.* 2010, 31: 455-61. <https://doi.org/10.1002/jcc.21334>
- Dallakyan, S. and A.J. Olson. Small-molecule library screening by docking with PyRx *Methods Mol Biol.* 2015, 1263: 243-50. https://doi.org/10.1007/978-1-4939-2269-7_19
- Blasco, R. and J.M. Coll. In silico screening for natural ligands to non-structural nsp7 conformers of SARS coronaviruses *ChemRxiv.* 2020. https://doi.org/10.26434/chemrxiv-12952115_v2
- Coll, J.M. Would it be possible to stabilize prefusion SARS-CoV-2 spikes with ligands? *ChemRxiv.* 2020. https://doi.org/10.26434/chemrxiv-13453919_v1
- Shityakov, S. and C. Forster. In silico predictive model to determine vector-mediated transport properties for the blood-brain barrier choline transporter *Adv Appl Bioinform Chem.* 2014, 7: 23-36. <https://doi.org/10.1002/aabc.563749>
- Reau, M., F. Langenfeld, J.F. Zagury and M. Montes. Predicting the affinity of Farnesoid X Receptor ligands through a hierarchical ranking protocol: a D3R Grand Challenge 2 case study *J Comput Aided Mol Des.* 2018, 32: 231-238. <https://doi.org/10.1007/s10822-017-0063-0>
- Schneider, N., S. Hindle, G. Lange, R. Klein, J. Albrecht, H. Briem, . . . M. Rarey. Substantial improvements in large-scale redocking and screening using the novel HYDE scoring function *J Comput Aided Mol Des.* 2012, 26: 701-23. <https://doi.org/10.1007/s10822-011-9531-0>
- Schneider, N., G. Lange, S. Hindle, R. Klein and M. Rarey. A consistent description of Hydrogen bond and Dehydration energies in protein-ligand complexes: methods behind the HYDE scoring function *J Comput Aided Mol Des.* 2013, 27: 15-29. <https://doi.org/10.1007/s10822-012-9626-2>
- Martignoni, M., G.M. Groothuis and R. de Kanter. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction *Expert Opin Drug Metab Toxicol.* 2006, 2: 875-94. <https://doi.org/10.1517/17425255.2.6.875>
- Celander, M., D.R. Buhler, L. Forlin, A. Goksoyr, C.L. Miranda, B.R. Woodin and J.J. Stegeman. Immunochemical relationships of cytochrome P450A3-like proteins in teleost fish *Fish Physiol Biochem.* 1996, 15: 323-32. <https://doi.org/10.1007/BF02112359>
- Connors, K.A., B. Du, P.N. Fitzsimmons, A.D. Hoffman, C.K. Chambliss, J.W. Nichols and B.W. Brooks. Comparative pharmaceutical metabolism by rainbow trout (Oncorhynchus mykiss) liver S9 fractions *Environ Toxicol Chem.* 2013, 32: 1810-8. <https://doi.org/10.1002/etc.2240>
- Ambrosio, L.F., C. Insfran, X. Volpini, E. Acosta Rodriguez, H.M. Serra, F.J. Quintana, . . . C.C. Motran. Role of Aryl Hydrocarbon Receptor (AhR) in the Regulation of Immunity and Immunopathology During Trypanosoma cruzi Infection *Front Immunol.* 2019, 10: 631. <https://doi.org/10.3389/fimmu.2019.00631>
- Abdullah, A., M. Maged, M.I. Hairul-Islam, I.A. Osama, H. Maha, A. Manal and H. Hamza. Activation of aryl hydrocarbon receptor signaling by a novel agonist ameliorates autoimmune encephalomyelitis *PLoS One.* 2019, 14: e0215981. <https://doi.org/10.1371/journal.pone.0215981>